Introduction {#section1-1076029619885184}
============

Platelets play a pivotal role in both hemostasis and thrombosis. Accordingly, the accurate measurement of platelet function is crucial to identify patients with suspected inherited or acquired dysfunction; moreover, evaluation of platelet function has become increasingly important for the monitoring of modern oral antiplatelet therapy.^[@bibr1-1076029619885184]^

The historical "gold standard" of platelet function testing is optical aggregometry (light transmission aggregometry \[LTA\]), which is based on the detection of light transmission changes due to platelet aggregation with a photometer after addition of a platelet agonist to platelet-enriched plasma (PRP). However, the LTA is a time-consuming and labor-intensive procedure, and many work steps have to be carried out manually, which increases the susceptibility to errors.^[@bibr2-1076029619885184][@bibr3-1076029619885184][@bibr4-1076029619885184][@bibr5-1076029619885184]--[@bibr6-1076029619885184]^ Additionally, although some efforts have been made toward standardization, the analytical processes still vary among laboratories, and data interpretation requires familiarity and expertise limiting the diagnostic implementation to highly specialized centers.^[@bibr7-1076029619885184],[@bibr8-1076029619885184]^

In recent years, several attempts have been made toward the automation of routine LTA in order to partly overcome the limitations of manual LTA assessment, all of which were carried out on different generations of the fully automated Sysmex CS coagulation analyzer.^[@bibr9-1076029619885184][@bibr10-1076029619885184][@bibr11-1076029619885184]--[@bibr12-1076029619885184]^ However, these studies were performed with limited sample numbers,^[@bibr9-1076029619885184]^ focused on technical aspects^[@bibr10-1076029619885184],[@bibr11-1076029619885184]^ or excluded samples derived from patients with inherited or acquired platelet dysfunction, limiting the informative value for the daily application of automated LTA in hemostaseologic routine.

We therefore aimed to test the agreement between the automated Sysmex CS-2100*i* coagulation analyzer (Siemens, Munich, Germany) against the standard-of-care routine light transmission aggregometer APACT 4004 (Labitec, Ahrensburg, Germany) for platelet function testing in a large number of samples involving healthy participants as well as samples from patients with inherited or acquired hemostaseologic disorders in daily routine practice.

Materials and Methods {#section2-1076029619885184}
=====================

Patient Selection and Material Preparation {#section3-1076029619885184}
------------------------------------------

Blood samples were collected as part of a routine visit at the Hemophilia Treatment Center of the University Clinic Frankfurt am Main. Patients were eligible to participate in the study if the following key inclusion criteria were fulfilled: Age \>18 years and a known inherited or acquired hemostaseologic disorder including patients with ASS and/or clopidogrel intake (cohort B = patients with ASS and/or clopidogrel intake; cohort C = patients with acquired or inherited hemostaseologic disorders other than ASS/clopidogrel-related). A separate reference cohort comprised of healthy participants (cohort A) with no (inherited or acquired) hemostaseologic disorder and no medication intake (eg, NSAR) for at least 10 days. Platelet counts above 100 × 10^9^/L were necessitated for subsequent platelet function testing, and patients with platelet counts below 100 × 10^9^/L were excluded from participation. A single blood sampling of 20 to 30 mL was collected in 10 mL sodium citrate buffer solution (S-Monovette; Sarstedt, Nümbrecht, Germany) yielding a final buffer--blood ratio of 1:9 according to the manufacturer's instructions and processed within 180 minutes in accordance with the local standard operation procedures that follow the LTA guidelines provided by the International Society of Thrombosis and Hemostasis^[@bibr2-1076029619885184]^ and Clinical and Laboratory Standards Institute (CLSI).^[@bibr5-1076029619885184]^ Nonadjusted equally aliquoted PRP was run simultaneously on 2 different analyzer platforms (see below) for a reading period of 600 seconds according to the CLSI guidelines^[@bibr5-1076029619885184]^ using different platelet agonists purchased from Hyphen Biomed, Neuville, France: adenosine diphosphate (ADP; final concentration in test cuvette: 5 µmol/L), arachidonic acid (AA, 1 mmol/L), ristocetin (RIS, 1 mg/mL), collagen (COL, 2 µg/mL), epinephrine (EPI, 5 µmol/L). It was ensured that the sample waiting time (particularly on the CS-2100*i*) was less than 180 minutes to avoid falsifying effects due to platelet sedimentation. Approval from the responsible institutional review board was obtained before data collection (approval number: EK 376/14). All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from all individual participants included in this study.

Analyzers {#section4-1076029619885184}
---------

Platelet aggregation was determined on 2 LTA-based analyzers:APACT 4004: The APACT 4004 (Elitech, Puteaux, France) is a 4-channel light transmission platelet aggregometer that was used as a reference instrument to evaluate platelet function. The APACT 4004 detects platelet aggregation in PRP by changes in light transmission (wavelength: 740 nm, 37°C). It has a graphical user interface with a touch screen. Parameters are presented automatically. The reaction curves are shown in real time with printing possibilities (screenshot and conventional printer). Results can be exported as an Excel file, a Word document, or as a pdf document. The APACT 4004 offers 4 channels for simultaneous determination of different methods with independently regulated stirrer speeds. The maximum measurement time is up to 60 minutes. Blanking of the optical channel was performed with platelet-poor plasma.Sysmex CS-2100*i* System: The Sysmex CS-2100*i* System is a fully automated high-performance coagulation analyzer provided by Siemens, Munich, Germany. According to the manufacturer, 48 samples can be processed for platelet function analysis within 1 hour for a respective measuring time of 5 minutes per sample; 24 samples can be processed for platelet function analysis within 1 hour for a respective measuring time of 10 minutes per sample. According to the manufacturer, the platelet sedimentation does not affect the sample stability and result validity up to 3 hours of waiting time in the analyzer. The automatic pipettor is coated to avoid platelet activation due to surface contact, and spontaneous clotting is not observed without the addition of agonists, according to the manufacturer. Blanking of the optical channel was automatically performed using platelet-poor plasma.

Parameters determined were Lag-phase (LagP), velocity (VEL), and maximum platelet aggregation (MA). As the Sysmex CS-2100*i* software does not provide an algorithm for de-aggregation measurements, this parameter was not assessed.

Statistical Analysis and Study Aim {#section5-1076029619885184}
----------------------------------

All variables collected were depicted using descriptive statistics. Differences between testing methods were evaluated using the paired *t* test. Correlation between methods was assessed using the Pearson *R* coefficient, and agreement was analyzed using the Passing-Bablok regression test and the Bland Altman analysis.

The primary study aim was to compare the performance of the automated Sysmex CS-2100*i* System to the APACT 4004 reference instrument with regard to acceptance criteria for validation (agreement) predefined as a Pearson correlation coefficient of *r* ≥ .85, a slope concordance of 0 ± 0.15, and an intercept concordance of 0 ± 10 in the Passing-Bablok analysis for each combination of thrombocyte agonist and the above-stated parameters. Data output was transferred to Microsoft Excel spreadsheets (Microsoft, Redmond, Washington). All variables collected were processed using Prism, Version 6 (GraphPad Software, San Diego, USA) and Analyse-it Method Validation Edition, Version 5.2 (Analyse-it Software, Leeds, UK).

Results {#section6-1076029619885184}
=======

Study Population and Correlation of Methods {#section7-1076029619885184}
-------------------------------------------

In total, between January 2016 and November 2016, 123 patient samples were investigated: 22 patients taking ASS, 20 patients taking clopidogrel (17 patients plus ASS; cohort B, n = 42), another 20 patients with inherited or acquired hemostaseologic disorders other than ASS or clopidogrel-related (cohort C, n = 20), and 61 healthy controls (cohort A, n = 61). Patients with hemostaseologic disorders comprised of inherited (non-2B) von Willebrand disease (VWD; n = 8), acquired VWD (n = 1), immune thrombocytopenia (n = 3), Glanzmann thrombasthenia (n = 1), thrombocyte dysfunction of unknown origin (n = 2), dysfibrinogenemia (n = 1), liver cirrhosis-related thrombocytopenia (n = 1), severe hemophilia A (n = 1), antithrombin deficiency (n = 1), and protein C deficiency (n = 1). Concentration of thrombocytes in the nonadjusted PRP probes (range, 110-1277 × 10^[@bibr9-1076029619885184]^/L) was well balanced between the testing methods (*P* = .48), and 90.4% (111/123) of all PRP samples showed platelet concentrations between 150 and 600 ×10^[@bibr9-1076029619885184]^/L. [Figure 1](#fig1-1076029619885184){ref-type="fig"} illustrates the MA, VEL, and LagP for the overall study cohort; the corresponding comparative descriptive statistics are summarized in [Tables 1](#table1-1076029619885184){ref-type="table"}-[3](#table3-1076029619885184){ref-type="table"}.

![Maximum aggregation, velocity, and LagP of the whole study cohort (n = 123) in dependence of the different platelet agonists. LagP indicates lag-phase.](10.1177_1076029619885184-fig1){#fig1-1076029619885184}

###### 

Comparative Descriptive Statistics of Maximum Aggregation.^a^

![](10.1177_1076029619885184-table1)

                              CS 2100i   APACT                                      
  --------------------- ----- ---------- ----------- ------ ------------ ---------- ---------
  Healthy controls                                                                   
   ADP                  61    90.9       82.8-95.6   94.2   87.9-99.5    \<.0001    .50^b^
   Collagen             61    93.5       85.3-97.5   92.2   88.2-99.9    .9849      .24^b^
   Ristocetin           61    89.4       80.5-96.1   95.6   88.8-100.4   \<.0001    −.09
   Arachidonic acid     61    92.1       82.1-98.6   92.1   85.2-99.1    .6406      .28^b^
   Epinephrine          61    92.6       75.8-99.3   92.9   81.5-99.4    .4356      .50^b^
  ASS                                                                                
   ADP                  22    85.0       33.9-93.8   83.2   30.6-92.3    .1747      .93^b^
   Collagen             22    80.7       17.3-94.8   83.8   24.5-92.8    .0270      .92^b^
   Ristocetin           22    87.7       56.4-94.8   87.7   56.5-93.8    .0869      .81^b^
   Arachidonic acid     22    5.5        0.4-18.7    14.1   3.8-32.4     \<.0001    .55^b^
   Epinephrine          22    63.4       28.7-63.4   67.3   41.8-96.1    .0222      .67^b^
  Clopidogrel (+ ASS)                                                                
   ADP                  20    71.3       38.9-81.5   67.8   26.8-82.4    .0049      .92^b^
   Collagen             20    52.0       21.1-84.9   60.2   29.4-87.2    .0005      .93^b^
   Ristocetin           20    86.4       57.5-91.5   80.8   55.6-92.5    .0386      .73^b^
   Arachidonic acid     20    5.3        0.5-87.5    14.0   3.1-92.6     \<.0001    .97^b^
   Epinephrine          20    50.9       28.0-93.9   63.7   43.1-88.0    .0003      .81^b^
  HD                                                                                
   ADP                  20    79.1       1.0-90.5    71.2   2.1-97.4     .1522      .83^b^
   Collagen             20    80.6       2.7-96.2    88.1   15.2-95.0    .2396      .96^b^
   Ristocetin           20    62.5       0.3-91.4    61.0   2.3-95.9     .9710      .88^b^
   Arachidonic acid     20    78.7       0.0-78.7    89.6   8.6-95.8     .0311      .89^b^
   Epinephrine          20    49.0       0.5-98.3    58.5   5.4-58.5     .2441      .77^b^
  Total cohort                                                                      
   ADP                  123   86.9       46.9-94.3   90.1   78.3-84.3    .96        .91^b^
   Collagen             123   91.1       76.8-84.3   90.0   79.6-85.9    .0003      .96^b^
   Ristocetin           123   87.7       77.4-84.7   90.8   79.0-86.7    .038       .90^b^
   Arachidonic acid     123   88.5       51.5-66.1   89.1   57.0-70.2    \< .0001   0.97^b^
   Epinephrine          123   86.7       67.9-77.3   86.3   73.2-81.0    .0002      0.87^b^

Abbreviations: ADP, adenosine diphosphate; HD, hemostaseologic disorder.

^a^ Adenosine diphosphate (final concentration in test cuvette: 5 µmol/L), arachidonic acid (1 mmol/L), ristocetin (1 mg/mL), collagen (2 µg/mL), and epinephrine (5 µmol/L).

^b^ Significant correlation.

###### 

Comparative Descriptive Statistics of Velocity.^a^

![](10.1177_1076029619885184-table2)

  Agonist               N     CS 2100i    APACT         *P* Value   Pearson *R*             
  --------------------- ----- ----------- ------------- ----------- ------------- --------- --------
  Healthy controls                                                                           
   ADP                  61    124.0       93.1-147.9    151.5       117.0-179.9   \<.0001   .46^b^
   Collagen             61    129.0       100.0-138.0   149.7       112.5-178.5   \<.0001   .027
   Ristocetin           61    91.0        43.8-133.6    104.3       68.4-164.6    \<.0001   .74^b^
   Arachidonic acid     61    135.0       101.1-156.7   156.0       102.0-197.4   \<.0001   .48^b^
   Epinephrine          61    52.0        33.1-74.6     59.8        29.3-92.0     \<.0001   .74^b^
  ASS                                                                                        
   ADP                  22    125.5       55.8-158.5    152.0       79.7-184.4    \<.0001   .84^b^
   Collagen             22    82.5        14.8-136.5    105.6       30.0-136.2    \<.0001   .95^b^
   Ristocetin           22    99.5        59.5-150.0    102.9       40.4-159.6    .2154     .90^b^
   Arachidonic acid     22    3.0         2.0-10.1      13.7        6.3-25.9      \<.001    .013
   Epinephrine          22    44.5        20.2-75.5     52.4        21.7-84.6     .0145     .75^b^
  Clopidogrel (+ ASS)                                                                        
   ADP                  20    96.5        60.2-132.4    122.1       78.2-173.7    \<.0001   .67^b^
   Collagen             20    51.5        27.1-111.7    64.7        39.9-156.2    .0005     .33
   Ristocetin           20    105.0       58.6-119.8    104.5       59.2-132.2    .0137     .83^b^
   Arachidonic acid     20    3.0         1.0-105.7     13.8        2.7-157.3     .0004     .98^b^
   Epinephrine          20    39.5        14.3-67.8     42.1        21.9-97.1     .0007     .92^b^
  HD                                                                                         
   ADP                  20    117.0       4.2-158.0     117.0       3.0-177.0     .0376     .91^b^
   Collagen             20    7.4-132.4   7.4-132.4     115.3       12.2-158.7    .0002     .97^b^
   Ristocetin           20    29.5        0.1-94.0      38.5        6.2-106.6     .0027     .90^b^
   Arachidonic acid     20    107.0       0.1-107.0     115.2       8.0-176.3     .0004     .97^b^
   Epinephrine          20    25.0        0.1-90.0      33.3        14.1-106.7    .0038     .72^b^
  Total cohort                                                                               
   ADP                  123   120.0       64.6-151.6    144.3       72.9-178.8    \<.0001   .80^b^
   Collagen             123   106.0       79.3-98.3     127.5       113.2-127.7   \<.0001   .94^b^
   Ristocetin           123   88.0        78.3-90.5     99.0        89.8-102.0    \<.0001   .87^b^
   Arachidonic acid     123   111.0       68.7-91.4     125.7       86.5-111.1    \<.0001   .95^b^
   Epinephrine          123   40.0        37.8-43.8     52.1        49.8-57.1     \<.0001   .77^b^

Abbreviations: ADP, adenosine diphosphate; HD, hemostaseologic disorder.

^a^ Adenosine diphosphate (final concentration in test cuvette: 5 µmol/L), arachidonic acid (1 mmol/L), ristocetin (1 mg/mL), collagen (2 µg/mL), and epinephrine (5 µmol/L).

^b^ Significant correlation.

###### 

Comparative Descriptive Statistics of LagP.^a^

![](10.1177_1076029619885184-table3)

  Agonist               N       CS 2100i   APACT        *P* Value   Pearson *R*             
  --------------------- ------- ---------- ------------ ----------- ------------- --------- ---------
  Healthy controls                                                                           
   ADP                  62      18.2       13.8-28.3    17.7        11.6-21.1     .19       .30^b^
   Collagen             61      62.9       48.6-83.6    46.0        35.4-63.5     \<.0001   .56^b^
   Ristocetin           62      24.5       15.1-46.9    14.7        10.2-30.0     \<.0001   .45^b^
   Arachidonic acid     61      58.1       41.2-93.3    24.4        19.0-99.0     \<.0001   −.005
   Epinephrine          62      49.3       31.7-130.7   22.8        10.8-151.0    .0018     .49^b^
  ASS                                                                                        
   ADP                  22      18.7       11.9-39.6    17.6        13.2-42.6     .87       −.06
   Collagen             22      71.0       8.7-163.9    52.4        15.0-70.8     .0041     −.43
   Ristocetin           22      23.1       11.8-37.0    12.5        10.8-27.0     .0002     .03
   Arachidonic acid             n/a        n/a          10.5        7.8-151.6     n/a       n/a
   Epinephrine          22      49.5       34.1-228.3   12.1        10.1-35.4     .0002     .13
  Clopidogrel (+ ASS)                                                                        
   ADP                  20      21.9       15.3-35.7    17.4        12.7-20.7     \<.0001   .32
   Collagen             20      86.7       0.0-112.8    61.5        40.9-78.4     .30       −.29
   Ristocetin           20      21.6       17.0-45.4    18.1        9.2-26.9      .0017     −.042
   Arachidonic acid     3       71.4       66.8-105.1   15.9        9.4-131.6     .044      .99^b^
   Epinephrine          20      53.8       20.7-271.0   11.9        9.6-33.6      .0006     .06
  HD                                                                                         
   ADP                  17/20   20.4       10.5-55.9    18.2        0.8-22.4      .026      .80^b^
   Collagen             20      74.2       2.5-218.6    57.1        10.7-81.9     .027      −.45^b^
   Ristocetin           13/20   45.3       22.8-199.2   12.3        10.3-28.1     .008      −.28
   Arachidonic acid     13/19   73.3       48.6-142.2   32.6        12.0-77.6     .0017     −.15
   Epinephrine          12/20   90.1       27.6-292.4   15.7        10.2-175.0    0.051     −.22
  Total cohort                                                                               
   ADP                  123     19.1       13.8-34.0    17.8        12.2-21.6     .0004     .20^b^
   Collagen             122     66.7       7.2-108.6    51.7        35.4-70.5     \<.0001   −.15^b^
   Ristocetin           116     24.6       15.1-59.2    12.6        10.2-28.3     \<.0001   .13
   Arachidonic acid     77      60.4       42.1-96.0    27.9        9.8-99.4      \<.0001   .08
   Epinephrine          115     50.4       32.4-202.9   19.6        10.2-129.9    \<.0001   .14

Abbreviations: ADP, adenosine diphosphate; LagP, lag-phase; HD, hemostaseologic disorder.

^a^ Adenosine diphosphate (final concentration in test cuvette: 5 µmol/L), arachidonic acid (1 mmol/L), ristocetin (1 mg/mL), collagen (2 µg/mL), and epinephrine (5 µmol/L).

^b^ Significant correlation.

Correlation of MA met the predefined acceptance criteria for agreement (*r* ≥ .85) across all subgroups of tested agonists ([Table 1](#table1-1076029619885184){ref-type="table"}). An excellent correlation of VEL between methods was also seen for the agonists COL (*r* = 0.94), RIS (*r* = 0.87), and AA (*r* = 0.94), whereas comparison of ADP (*r* = .80) and EPI (*r* = .77) induced VEL failed to meet the predefined acceptance criteria ([Table 2](#table2-1076029619885184){ref-type="table"}) but still yielded statistical significant correlation. There was weak or no correlation between the testing methods in regard to the LagP, irrespective of the used agonist in the overall study population (*r* ≤ .20; [Table 3](#table3-1076029619885184){ref-type="table"}).

Platelet maximum aggregation was consistent between the analyzers in most subgroups; still, we encountered a significantly reduced AA-induced MA in samples derived from patients taking ASS and/or clopidogrel analyzed with the CS-2100*i* compared to the APACT 4004. Velocity of aggregation was systematically lower across all agonists measured with the CS-2100*i*; however, this finding was less pronounced in samples derived from patients with hemostaseologic disorders. Visual comparison of aggregation curves overall showed consistent kinetics; a representative example for a 300-second measurement period in material derived from a patient with VWD type I is shown in [Figure 2](#fig2-1076029619885184){ref-type="fig"}.

![Representative aggregation curves in a patient with von Willebrand disease (top, APACT 4004; bottom, CS-2100*i*).](10.1177_1076029619885184-fig2){#fig2-1076029619885184}

Agreement of Testing Methods {#section8-1076029619885184}
----------------------------

[Figure 3](#fig3-1076029619885184){ref-type="fig"} illustrates the agreement between the testing methods according to the Bland Altmann analysis. With regard to MA, there was good agreement between the CS-2100*i* and APACT 4004 for ADP (95% limits for agreement, −15.9 to 15.9) and COL (95% limits for agreement, −15.1 to 10.7) with evidence for systematic lower values in patients with an MA below 50% with the CS-2100*i*. The dispersion of values for MA across the agonists RIS (95% limits for agreement, −20.3 to 16.8), AA (95% limits for agreement, −23.9 to 14.4), and EPI (95% limits for agreement, −29.8 to 20.8) was higher, especially for lower MA values indicative of a systematic bias to lower measurements below a threshold of 50% MA with the CS-2100*i* compared to the APACT 4004. [Figure 4](#fig4-1076029619885184){ref-type="fig"} displays the Passing Bablok indicators and its 95% confidence intervals in relation to the predefined acceptance criteria for agreement. Overall (with the exception of RIS-induced VEL), the agreement between methods missed the predefined level of acceptance.

![Bland-Altmann analysis between the CS-2100*i* and APACT of the whole study cohort (n = 123): curves in dependence of the different platelet agonists for maximum aggregation, velocity, and LagP. LagP indicates lag-phase.](10.1177_1076029619885184-fig3){#fig3-1076029619885184}

![Agreement blot for the Passing Bablok method for maximum aggregation, velocity, and LagP; dotted lines indicate predefined significance intervals for agreement. LagP indicates lag-phase.](10.1177_1076029619885184-fig4){#fig4-1076029619885184}

We therefore questioned the clinical significance of missing statistical agreement between the testing methods focusing on MA: The median of absolute differences and the corresponding 95th percentiles (in parenthesis) for the agonists ADP, COL, RIS, AA, and EPI were 4.7 (16.4), 3.2 (15.6), 5.9 (16.5), 4.8 (19.6), and 6.4 (28.2), respectively, between the CS-2100*i* and the APACT 4004. Furthermore, we focused on those patients with inherited or acquired hemostaseologic disorders (ASS and/or clopidogrel intake, n = 42; VWD, n = 9; genetically confirmed Glanzmann thrombasthenia, n = 1; thrombocyte dysfunction of unknown origin, n = 2) who were all successfully identified with the CS-2100*i* system ([Figure 5](#fig5-1076029619885184){ref-type="fig"}) in reference to the values measured with the APACT 4004.

![Maximum aggregation values for single sample pairs in patients with inherited or acquired platelet function disorders. \*The patient with genetically confirmed Glanzmann thrombasthenia; ^\#,§^1 patient each with platelet dysfunction of unknown origin.](10.1177_1076029619885184-fig5){#fig5-1076029619885184}

Agreement in Dependence of PRP Concentration {#section9-1076029619885184}
--------------------------------------------

We next sought to determine the agreement of the CS-2100*i* system in dependence of the platelet concentration in PRP using linear regression. We found a significant influence of the platelet concentration in PRP on the agreement of the CS-2100*i* system in COL-induced MA (*P* \< .001) with lower agreement between the analyzers in lower PRP concentrations; however, the overall deterministic impact was low (Pearson *R*2 = .098). There was no statistically significant dependence for the other agonists (ADP \[*P* = .29\], RIS \[*P* = .62\], AA \[*P* = .14\], and EPI \[*P* = .54\]). In addition, we examined the impact of PRP thrombocyte concentration on the MA values in both testing methods: There were significant relationships across the agonists ADP, COL, and EPI for both coagulation analyzers; in particular, there were lower MA values in those samples with lower PRP concentrations. However, the overall impact was low for all agonist subgroups but highest for ADP tested with the CS-2100*i* (Pearson *R*2 = .18).

Discussion {#section10-1076029619885184}
==========

The current study aimed to test the agreement between the standard-of-care LT aggregometer APACT 4004 against the fully automated coagulation analyzer Sysmex CS-2100*i* System and was carried out under real-world conditions at a single comprehensive care hemophilia treatment center.

We saw an excellent overall correlation for MA and a good correlation for VEL between the methods. In terms of intermethod agreement, the overall concordance between the testing methods for MA and VEL was good yet insignificant according to the predefined acceptance criteria. Less agreement was observed for LagP between the CS-2100*i* and the APACT 4004, underscoring the necessity of defining separate reference values for automated coagulation analyzers. Platton et al provided first reference values for healthy volunteers in dependence of the final agonist concentration in the test cuvette.^[@bibr11-1076029619885184]^ We confirm and refine the published reference values for agonist concentrations analogous to the CLSI guidelines^[@bibr5-1076029619885184]^ by narrowing the published reference range. In addition, we provide first reference values for thrombocyte function impairment due to ASS and/or clopidogrel intake on a CS-2100*i* that may be used for local laboratory verification. It is important to mention that our study did not aim to identify or establish a platelet reactivity threshold for patients considered to be nonresponders (high post-treatment platelet reactivity) to ASS/clopidogrel treatment (cohort B) and such values are currently not provided by the manufacturer either.

In general, some attempts^[@bibr13-1076029619885184],[@bibr14-1076029619885184]^ were made to establish cutoff values for LTA-assessed platelet function in clopidogrel-treated patients; however, to the best of our knowledge, a broadly adapted consensus for the identification of nonresponders to antiplatelet therapy has not been established yet. Additionally, there are conflicting results regarding the clinical benefit of tailored antiplatelet treatment based on platelet function monitoring, and most randomized prospective trials have failed to show improvement in patient outcomes.^[@bibr15-1076029619885184][@bibr16-1076029619885184]--[@bibr17-1076029619885184]^ More clinical trials involving automated LTA, such as the CS-2100*i*, are mandatory to define specific cutoff values for antiplatelet nonresponsiveness. The minor role of post-treatment platelet monitoring in clinical routine explains our long recruitment period of 11 months; in particular, the filling of cohort b with a reasonable number of patients, referred for post-treatment monitoring, was time consuming.

Absolute differences for MA between the testing methods were low for most patient-derived samples, and more importantly, all patients with inherited and acquired thrombocyte dysfunction as referenced by the APACT 4004 were successfully identified with the CS-2100*i*. Conclusively, although our study did not meet its primary aim, and the predefined criteria for agreement between the testing methods were only partially achieved, we consider the statistical disagreement for MA and VEL as clinically insignificant for routine and high-throughput purposes.

Platelet function testing is a multistep, error-prone procedure that requires a high standardization of preanalytical and analytical procedures and still varies in detail between the stated international guidelines and among laboratories. We therefore fully acknowledge that the results presented here may only be valid for comparable settings in terms of preanalytical sample preparation as well as type and final concentrations of the used agonists. According to the CLSI guidelines, PRP adjustment is recommended for platelet function testing and was not performed in our study to avoid delayed sample preparation and sample instability. Indeed, platelet concentration in PRP had statistically significant influence on the accuracy of the CS-2100*i* System as well as MA values of both testing methods. However, the overall influence was only small, and previous studies carried out with automated coagulation analyzers suggest no significant effect on MA.^[@bibr10-1076029619885184]^ Additionally, we did not test different agonist concentrations to examine their influence on MA, VEL, and LagP measurements. It has been shown previously that in particular increasing concentrations of ADP significantly influence MA levels in CS-2X00 systems^[@bibr11-1076029619885184]^; therefore, transferring our results of method agreement to different agonist concentrations or different agonists (eg, PGE1) should be done with caution. Additionally, conclusions cannot be drawn to patients with rare platelet function disorders, particularly storage pool defects as there were no such participants in our study. Finally, we did not test for repeatability of the CS-2100*i* System; however, others did and found a high intramethod reliability for the CS-2100*i*.^[@bibr10-1076029619885184]^

In conclusion, performing automated LTA with the CS-2100*i* is a highly standardized procedure that proved to be capable of identifying patients with normal and acquired platelet impairment as suggested by the standard-of-care LTA analysis (APACT 4004). Additionally, all 3 patients with inherited platelet dysfunction were successfully identified. Although the primary aim of statistical agreement between the standard-of-care LTA and the automated coagulation analyzer was not met, we consider the overall accuracy of the CS-2100*i* as sufficient for routine platelet function testing. It is important to define distinct reference ranges for automated LTA assessment that may differ among testing methods. The development of automated platelet function instrumentation represents a decisive step in the simplification of platelet function testing in clinical routine, not only for laboratorians who struggle with current cumbersome methodology but also for clinicians who need faster result reporting times.

More studies are needed to evaluate the performance of automated LTA analyzers in a wider range of utility, for example, with alternative platelet agonists or in patients with rare inherited platelet disorders.
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